title: Prevalence of hepatitis A and B markers and vaccine indication in cirrhotic patients evaluated for liver transplantation in Spain.
abstract: Vaccination against hepatitis A virus (HAV) and hepatitis B virus (HBV) is generally recommended for patients with chronic liver disease and those evaluated for liver transplantation in the absence of immunity. HAV and HBV infections after liver transplantation are frequent and associated with a worse prognosis. The data suggest that the number of patients with chronic liver disease without naturally acquired immunity against HAV and HBV is substantial, and that new vaccination strategies are needed. The aim of this study was to determine the level of immunity from hepatitis A and B infections and the need for HBV and HAV vaccination among cirrhotic patients evaluated for liver transplantation. We studied HBV and HAV serological markers (HbsAg, anti-HBc, anti-HBs, IgG anti-HAV) in 451 cirrhotic patients evaluated for liver transplantation to investigate the association with gender, age, and etiology of cirrhosis. Negative HBV markers were observed in 57% of patients with 43% displaying one positive HBV marker: HBsAg (+), 9.5%; anti-HBc (+)/anti-HBs (-), 11.5%; anti-HBc (-)/anti-HBs(+), 4.2%; anti-HBc(+)/anti-HBs(+), 17.7%. HBV vaccine indication established in 68.5% of patients was greater among women and hepatitis C virus-negative patients. No differences were observed in age or cause of cirrhosis. HAV vaccination indicated in 6.7% of patients (IgG anti-HVA-negative) was greater among patients with negative HBV markers (9.3% vs 3.3%, P = .018) and younger patients (25.3% of patients </=45 years). In conclusion, there are frequent indication, for HBV vaccine among cirrhotic patients evaluated for liver transplantation, as is time for HAV vaccine, especially among patients younger than 45 years of age.
authors.affiliation: Department of Digestive Diseases, Virgen del Rocío University Hospital, Seville, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Aoufi
authors.forename: J M
authors.initials: JM
authors.lastname: Pascasio
authors.forename: J M
authors.initials: JM
authors.lastname: Sousa
authors.forename: M
authors.initials: M
authors.lastname: Sayago
authors.forename: M T
authors.initials: MT
authors.lastname: Ferrer
authors.forename: E
authors.initials: E
authors.lastname: Gómez-Delgado
authors.forename: M D
authors.initials: MD
authors.lastname: De la Cruz
authors.forename: J M
authors.initials: JM
authors.lastname: Alamo
authors.forename: M A
authors.initials: MA
authors.lastname: Gómez-Bravo
authors.forename: A
authors.initials: A
authors.lastname: Bernardos
authors.forename: J L
authors.initials: JL
authors.lastname: Márquez
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000032:analysis; D005260:Female; D006506:Hepatitis A / Q000453:epidemiology / Q000276:immunology*; D022362:Hepatitis A Vaccines; D006509:Hepatitis B / Q000453:epidemiology / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000032:analysis*; D017325:Hepatitis B Vaccines; D006801:Humans; D008103:Liver Cirrhosis / Q000601:surgery* / Q000821:virology*; D016031:Liver Transplantation / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D013030:Spain; D055815:Young Adult
chemical_list: D015415:Biomarkers; D022362:Hepatitis A Vaccines; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines